甲氨蝶呤治疗与皮肤恶性黑色素瘤风险:一项回顾性比较注册队列研究
BACKGROUND: Methotrexate (MTX) is frequently used as an immunosuppressive drug in inflammatory diseases. It is controversial and it has not been thoroughly investigated whether MTX increases the risk of cutaneous malignant melanoma (CMM).…
要点
- 亚组分析中风险差异仅见于治疗开始时年龄>70岁的女性。
核心结论
- 甲氨蝶呤治疗患者皮肤恶性黑色素瘤风险小幅但显著增加,风险增幅低于既往观察。
研究设计与样本
- 回顾性比较注册队列研究,数据来自瑞典国家卫生与福利委员会及瑞典癌症登记库。
主要发现
- 亚组分析中,组间差异仅见于治疗开始时年龄>70岁的女性。
- 研究期间甲氨蝶呤暴露与未暴露患者的发病率无显著差异。
临床怎么用
- 对接受甲氨蝶呤治疗的患者,尤其治疗开始时年龄>70岁的女性,应关注皮肤恶性黑色素瘤的监测。
- 风险绝对增幅较小,临床决策时应结合患者个体情况权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methotrexate (MTX) is frequently used as an immunosuppressive drug in inflammatory diseases. It is controversial and it has not been thoroughly investigated whether MTX increases the risk of cutaneous malignant melanoma (CMM). OBJECTIVES: The aim of the present study was to investigate whether MTX exposure increases the risk for CMM. METHODS: A retrospective cohort study was conducted using statistics from the National Board of Health and Welfare. All patients over 18 years in the time period August 2005 to December 2014 that were dispensed MTX from Swedish pharmacies were registered (n = 101 966). For every MTX-exposed patient, five age- and sex-matched patients who had been dispensed a random drug other than MTX during the same time period were randomly selected (n = 509 279). The lists were matched with the Swedish Cancer Registry. RESULTS: Overall, a small but statistically significant (P < 0·001) risk increase for CMM was observed in MTX-exposed patients compared with patients without MTX exposure. The Kaplan-Meier estimates for the 5-year risk of CMM was 0·48% [95% confidence interval (CI) 0·43-0·53] in the MTX-exposed group and 0·41% (95% CI 0·39-0·43) in the MTX-unexposed group. However, in a subgroup analysis, the difference between the groups was preserved only in women older than 70 years at treatment start. Moreover, there was no significant difference in incidences between the MTX-exposed and MTX-unexposed patients in the time period. CONCLUSIONS: Our results suggest a small but significant increase in risk for CMM in patients treated with MTX. However, the risk increase observed was considerably lower than in earlier observations.
引用
- Polesie S, Gillstedt M, Sönnergren HH, et al. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study. Br J Dermatol. 2017. PMID: 27858996. doi:10.1111/bjd.15170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。